JP7056858B2 - 新規な組換え型二機能性融合タンパク質、その調製方法および用途 - Google Patents

新規な組換え型二機能性融合タンパク質、その調製方法および用途 Download PDF

Info

Publication number
JP7056858B2
JP7056858B2 JP2019542396A JP2019542396A JP7056858B2 JP 7056858 B2 JP7056858 B2 JP 7056858B2 JP 2019542396 A JP2019542396 A JP 2019542396A JP 2019542396 A JP2019542396 A JP 2019542396A JP 7056858 B2 JP7056858 B2 JP 7056858B2
Authority
JP
Japan
Prior art keywords
antibody
fusion protein
cd20mab
cancer
bifunctional fusion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019542396A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020509737A5 (enExample
JP2020509737A (ja
Inventor
ティアン、ウェンジ
リ、ソン
Original Assignee
イミューンオンコ バイオファーマシューティカルズ （シャンハイ） カンパニー リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イミューンオンコ バイオファーマシューティカルズ （シャンハイ） カンパニー リミテッド filed Critical イミューンオンコ バイオファーマシューティカルズ （シャンハイ） カンパニー リミテッド
Publication of JP2020509737A publication Critical patent/JP2020509737A/ja
Publication of JP2020509737A5 publication Critical patent/JP2020509737A5/ja
Application granted granted Critical
Publication of JP7056858B2 publication Critical patent/JP7056858B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2019542396A 2017-03-15 2018-03-15 新規な組換え型二機能性融合タンパク質、その調製方法および用途 Active JP7056858B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201710151979.6A CN108623689B (zh) 2017-03-15 2017-03-15 新型重组双功能融合蛋白及其制备方法和用途
CN201710151979.6 2017-03-15
PCT/CN2018/079187 WO2018166507A1 (zh) 2017-03-15 2018-03-15 新型重组双功能融合蛋白及其制备方法和用途

Publications (3)

Publication Number Publication Date
JP2020509737A JP2020509737A (ja) 2020-04-02
JP2020509737A5 JP2020509737A5 (enExample) 2021-12-23
JP7056858B2 true JP7056858B2 (ja) 2022-04-19

Family

ID=63522802

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019542396A Active JP7056858B2 (ja) 2017-03-15 2018-03-15 新規な組換え型二機能性融合タンパク質、その調製方法および用途

Country Status (6)

Country Link
US (2) US11407841B2 (enExample)
EP (1) EP3626747B1 (enExample)
JP (1) JP7056858B2 (enExample)
CN (2) CN108623689B (enExample)
ES (1) ES2960311T3 (enExample)
WO (1) WO2018166507A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7193058B2 (ja) * 2018-08-08 2022-12-20 イミューンオンコ バイオファーマシューティカルズ （シャンハイ） インコーポレイテッド Ｃｄ４７およびｈｅｒ２を標的とする組換え二機能性タンパク質
BR112021008486A2 (pt) * 2018-11-01 2021-10-26 Shandong New Time Pharmaceutical Co., Ltd Anticorpo biespecífico e seu uso
US20220056135A1 (en) * 2018-12-21 2022-02-24 Ose Immunotherapeutics Bifunctional anti-pd-1/sirpa molecule
CN111484558B (zh) * 2019-01-28 2023-02-17 上海交通大学 信号调节蛋白α片段-抗FcRn单链抗体融合蛋白及其制备与应用
CN111423515A (zh) * 2020-03-23 2020-07-17 倍而达药业（苏州）有限公司 一种cd20/cd47双特异性抗体及应用
CN113896802A (zh) * 2021-10-09 2022-01-07 宜明昂科生物医药技术（上海）有限公司 靶向cd47和cd38的重组融合蛋白及其制备和用途
CN113956363B (zh) 2021-10-13 2023-03-31 宜明昂科生物医药技术（上海）股份有限公司 靶向cd47和cd24的重组融合蛋白及其制备和用途
WO2023072217A1 (en) * 2021-10-28 2023-05-04 Guangzhou Lintonpharm Co., Ltd. Fusion proteins targeting cd3 and cd47
WO2024179545A1 (zh) * 2023-03-01 2024-09-06 上海津曼特生物科技有限公司 包含cd20/cd47阻断双功能融合蛋白的联合用药物及其用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016022971A1 (en) 2014-08-08 2016-02-11 The Board Of Trustees Of The Leland Stanford Junior University Sirp alpha-antibody fusion proteins
WO2016024021A1 (en) 2014-08-15 2016-02-18 Merck Patent Gmbh Sirp-alpha immunoglobulin fusion proteins
JP2016514676A (ja) 2013-03-15 2016-05-23 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ 四価二重特異性抗体

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3298043T3 (da) * 2015-05-18 2021-02-15 Ab Initio Biotherapeutics Inc SIRP-polypeptidsammensætninger og fremgangsmåder til anvendelse

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016514676A (ja) 2013-03-15 2016-05-23 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ 四価二重特異性抗体
WO2016022971A1 (en) 2014-08-08 2016-02-11 The Board Of Trustees Of The Leland Stanford Junior University Sirp alpha-antibody fusion proteins
WO2016024021A1 (en) 2014-08-15 2016-02-18 Merck Patent Gmbh Sirp-alpha immunoglobulin fusion proteins

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Clin Cancer Res, 2016 Apr 28, vol. 22, no. 20, pp. 5109-5119
mAbs, 2015.08.26, vol. 7, no. 5, pp. 946-956

Also Published As

Publication number Publication date
WO2018166507A1 (zh) 2018-09-20
US20220010031A1 (en) 2022-01-13
EP3626747B1 (en) 2023-07-19
CN110300766B (zh) 2022-04-12
EP3626747A1 (en) 2020-03-25
ES2960311T3 (es) 2024-03-04
CN108623689A (zh) 2018-10-09
CN108623689B (zh) 2020-10-16
US11407841B2 (en) 2022-08-09
JP2020509737A (ja) 2020-04-02
US20200095339A1 (en) 2020-03-26
EP3626747A4 (en) 2021-06-30
CN110300766A (zh) 2019-10-01

Similar Documents

Publication Publication Date Title
JP7690468B2 (ja) 多様な固形腫瘍を処置するためのｂ７ｈ３（ｃｄ２７６）を標的とする高親和性ナノボディ
CN109963591B (zh) B7h3抗体-药物偶联物及其医药用途
JP2024053016A (ja) Ｇタンパク質共役受容体を標的化する抗体および使用の方法
CN109071654B (zh) 靶向Fc受体样5的抗体及使用方法
EP4215549A1 (en) Anti-4-1bb-anti-pd-l1 bispecific antibody, and pharmaceutical composition and use thereof
CN110627906A (zh) 抗pd-l1/4-1bb双特异性抗体及其用途
JP2020509737A (ja) 新規な組換え型二機能性融合タンパク質、その調製方法および用途
JP6212497B2 (ja) トランスフェリン受容体を特異的に認識できる抗体
EP4112647A1 (en) Anti-cd47/anti-pd-l1 antibody and applications thereof
RS61781B1 (sr) Antitela koja ciljaju antigen za sazrevanje b-ćelija i postupci upotrebe
US12565534B2 (en) Nano-antibody targeting CAIX antigen and application thereof
CN112442122B (zh) 阻断型pd-1纳米抗体及其编码序列和用途
KR20230169944A (ko) Mage-a4 펩티드-mhc 항원 결합 단백질
JP2023529633A (ja) 抗ｂ７－ｈ３抗体ならびにその調製および適用
KR20230034944A (ko) Abcb5에 특이적인 항체 및 그의 용도
CN115397857B (zh) 一种抗pd-l1和pd-l2抗体及其衍生物和用途
CN114685666A (zh) 抗间皮素纳米抗体及其应用
CN120271715A (zh) 抗体及其药物偶联物和用途
KR20200104279A (ko) Herg1 및 herg/인테그린 베타 1에 결합하는 동종 및 이중특이적 항체
WO2026002239A1 (zh) 靶向cd155的抗原结合蛋白及其应用
WO2025218621A1 (zh) 靶向muc1的抗原结合蛋白
WO2024093147A1 (zh) 一种特异性结合CD44的v5外显子的抗体及其用途
TW202400651A (zh) 抗cd200r1抗體
CN118725133A (zh) 双特异性抗体及其用途
HK40002168B (en) Antibodies targeting fc receptor-like 5 and methods of use

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201027

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210813

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210824

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20211109

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220308

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220328

R150 Certificate of patent or registration of utility model

Ref document number: 7056858

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250